Jaguar Animal Health Inc (JAGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jaguar Animal Health Inc (JAGX) has a cash flow conversion efficiency ratio of -0.561x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.83 Million) by net assets ($-15.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See JAGX net asset quality score to measure how much of total assets are equity-financed.
Jaguar Animal Health Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Jaguar Animal Health Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Jaguar Animal Health Inc to evaluate the quality of earnings relative to operating cash generation.
Jaguar Animal Health Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jaguar Animal Health Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lucapa Diamond Company Ltd
AU:LOM
|
-0.039x |
|
Rayong Wire Industries Public Company Limited
BK:RWI
|
-0.006x |
|
Nevada Sunrise Gold Corp
V:NEV
|
-0.157x |
|
Reklaim Ltd
V:MYID
|
-0.299x |
|
Manchester and London Investment Trust plc
LSE:MNL
|
-0.011x |
|
Novakand Pharma AB (publ)
ST:LARK
|
-0.029x |
|
Gibb River Diamonds Ltd
AU:GIB
|
-1.410x |
|
PAVmed Inc
NASDAQ:PAVM
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Jaguar Animal Health Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Jaguar Animal Health Inc from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see JAGX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-18.69 Million | $5.80 Million | -0.310x | +93.14% |
| 2024-12-31 | $6.49 Million | $-29.38 Million | -4.525x | +33.34% |
| 2023-12-31 | $4.90 Million | $-33.24 Million | -6.788x | -127.81% |
| 2022-12-31 | $-1.36 Million | $-33.10 Million | 24.413x | +927.47% |
| 2021-12-31 | $11.85 Million | $-34.97 Million | -2.950x | -232.18% |
| 2020-12-31 | $17.20 Million | $-15.28 Million | -0.888x | +53.66% |
| 2019-12-31 | $10.67 Million | $-20.46 Million | -1.917x | +54.61% |
| 2018-12-31 | $5.38 Million | $-22.73 Million | -4.223x | -641.85% |
| 2017-12-31 | $17.26 Million | $-9.82 Million | -0.569x | -109.69% |
| 2016-12-31 | $-2.45 Million | $-14.41 Million | 5.873x | +280.47% |
| 2015-12-31 | $4.40 Million | $-14.32 Million | -3.254x | +34.70% |
| 2014-12-31 | $1.10 Million | $-5.46 Million | -4.984x | -46.54% |
| 2007-12-31 | $5.40 Million | $-18.37 Million | -3.401x | -- |
About Jaguar Animal Health Inc
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. I… Read more